Glaucoma is a group of eye diseases characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage, which is most commonly associated with elevated levels of intraocular pressure. Glaucoma is a chronic condition that progresses slowly over long periods of time and can have a devastating impact on a patient’s vision and quality of life. Reducing intraocular pressure currently is the only proven treatment for glaucoma.
Hydrus™ Is a Microstent, developed by Ivantis, for the treatment of patients with primary open angle glaucoma (POAG) and cataracts. The Hydrus procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions. The enrollment for this study is closed.
CyPass® is a Microstent, developed by Alcon, for the treatment of patients with mild to moderate primary open-angle glaucoma (POAG) and cataracts. The CyPass implantation procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions. After we concluded a two-year trial with successful results, we are now extending the observation period to five years. The enrollment for this study is closed.
CyPass Micro-Stent (Post-Approval)
The CyPass Micro-stent received FDA approval in 2016 for treatment of patients with mild to moderate primary open-angle glaucoma (POAG) undergoing cataract surgery. The purpose of this study is to assess placement, stability, and intraocular pressure (IOP)-lowering effects of the CyPass in a post-market setting. The enrollment for this study is open and we are currently screening patients to participate in this study.
A tiny medical product called the Travoprost Intraocular Implant, developed by Glaukos, is being tested in an investigational study to help alleviate high eye pressure. The goal of the Travoprost Intraocular Implant is to lower your eye pressure (intraocular pressure or IOP). The Travoprost Intraocular Implant slowly releases Travoprost, the active drug in a commonly used glaucoma eyedrop. You can visit this website for more information: http://glaukosclinicaltrials.com. The enrollment for this study is open and we are currently screening patients to participate in this study.
Chances are high if you are in your 40s or beyond you have started to notice the effects of presbyopia. The loss of near vision and the ability to perform tasks that require near vision is part of the normal aging process. In the eye, the crystalline lens is located just behind the iris and the pupil. Tiny ciliary muscles pull and push the lens, adjusting its curvature, and thereby adjusting the eye’s focal power to bring objects into focus. As individuals age, the lens becomes less flexible and elastic, and the muscles become less powerful. Because these changes result in inadequate adjustment of the lens of the eye for various distances, objects that are close will appear blurry. The major cause of presbyopia is loss of elasticity of the lens of the eye. Loss of ciliary muscle power, however, is also believed to contribute to the problem.
Another alternative to correct presbyopia is the VisAbility micro-insert system by Refocus Group. The procedure is a minimally invasive outpatient procedure, which typically takes 20 to 30 minutes per eye. Four small plastic implant segments (about the size of a grain of rice) are surgically placed into the white of your eyes. The segments are small, normally hidden by the eyelids and are generally not noticeable after placement. It is anticipated that these implant segments will create additional space inside the eye to restore the natural tension of the muscle tissue inside the eye. The enrollment for this study is closed.
Astigmatism is a condition where the cornea (front surface) of the eye, is not curved uniformly, it is shaped more like a football than spherical like a baseball. With astigmatism, the light rays passing through the cornea do not focus on a single point of the retina. This may cause objects both near and far away to appear blurry, shaded or elongated. An intraocular lens designed to reduce astigmatism is called a “toric” IOL. Cataract patients who have astigmatism, and who do not want to wear glasses to see clearly at distance can choose Toric intraocular lenses to be implanted during surgery.
We are conducting two different studies related with Toric intraocular lenses.
Post-Approval Study of the Tecnis Toric IOL Models ZCT300 and ZCT400
This study sponsored by Abbott evaluates the rates of visual distortion in patients with cataract implanted with the TECNIS Toric IOLs (ZCT300 and ZCT400) The TECNIS Toric IOLs are marketed in the US, Europe and other countries worldwide. The enrollment for this study is closed.
Clinical Performance of the Cassini TCA for Toric IOLs
This study enrolls patients that will have cataract surgery with Toric intraocular lenses, used to correct astigmatism, and compares actual and simulated Toric IOL calculations with different keratometric measurement devices, including the Cassini topographer. The enrollment for this study is closed.
Quality of Vision of Patients Implanted with Intraocular Lens (IOL) After Cataract Surgery
In some cases, healthy patients with successful cataract surgeries report visual disturbances despite a normal observation from the physician’s perspective. To further our understanding of these phenomena, ClarVista is sponsoring a patient reported outcome study on healthy, post-surgical cataract patients that do not have any other ocular conditions. The primary goal for this study is to understand how different intraocular lenses interact with different patients. Through an in-depth questionnaire that asks about visual issues, we can evaluate which visual problems are common among different IOLs. The results from this study will give us a better understanding of intraocular lens compatibility and allow us to refine our lens recommendations. The enrollment for this study is closed.
For more information about our clinical studies and to see if you qualify please contact:
Ashley Owyang, OD
Clinical Study Coordinator